Both worlds over time
Technical and news signals of the last 90 days on one timeline.
AMGN fundamental outlook?
From news analysis — different time windows than the trading horizons above
- Amgen plunged over 10% and was the worst performer in the Dow, S&P 500, and Nasdaq 100 after Novartis's pelacarsen Phase 3 failure raised doubts about Amgen's rival Lp(a) drug olpasiran.
- BMO Capital downgraded AMGN from Outperform to Market Perform, citing the stock's 34% year-to-date gain as leaving little room for pipeline disappointment.
- The selloff was amplified by a sector-wide biotech rout following Novartis's third clinical-trial setback in a week, with Amgen leading index losses.
- The binary catalyst is the Phase 3 OCEAN(a)-Outcomes study for olpasiran — a positive readout would reverse the negative read-through; a failure would validate the bear case.
- Separately, European regulators backed withdrawal of Amgen's Tavneos due to data-integrity issues, threatening EU revenue from that product.
- 11 of 13 signals are Bearish with impact scores of 8-10, indicating high-conviction negative sentiment rather than noise.
- The only bullish signal is structural: Amgen remains a top holding of the PBE biotech ETF and is recommended by The Motley Fool for long-term growth.
Amgen shares were hammered over the past week, plunging as much as 10% and becoming the worst performer in the Dow, S&P 500, and Nasdaq 100 after Novartis reported a Phase 3 failure for its Lp(a)-lowering cardiovascular drug pelacarsen. The read-through is direct: Amgen's own investigational siRNA therapy olpasiran, currently in the OCEAN(a)-Outcomes study, targets the same mechanism, and investors fear comparable efficacy or safety hurdles. The selloff was compounded by a BMO Capital downgrade from Outperform to Market Perform, citing the stock's 34% year-to-date run, and by a broader biotech sector rout tied to Novartis's third clinical-trial setback in a week. Amgen also faces a separate regulatory overhang: European regulators backed withdrawal of Tavneos due to data-integrity issues, threatening EU sales. The lone bullish signal is structural — Amgen remains a top holding of the PBE biotech ETF and is recommended by The Motley Fool for long-term growth. Net: 11 of 13 signals are Bearish, with impact scores of 8-10 and confidence of 65-72, making this a high-conviction negative read. The key binary catalyst ahead is the Phase 3 OCEAN(a)-Outcomes readout for olpasiran; until then, the stock trades on sentiment and sector contagion.
43 days ago · Based on 13 signals
AMGN remains under pressure in the 1-7 day window as the Novartis read-through and BMO downgrade digest; watch for stabilization near the post-selloff lows, with any bounce likely capped by sector-wide biotech weakness. A close below the 10% drawdown level would signal further downside toward the next support zone.
Over 1-4 weeks, AMGN trades on biotech sector sentiment and any incremental news on the OCEAN(a)-Outcomes timeline; the Tavneos EU withdrawal adds a modest revenue headwind. Absent a positive pipeline update, the stock likely consolidates at lower levels as investors await clarity on olpasiran.
Over 1-3 months, the structural driver is the OCEAN(a)-Outcomes readout — a success re-rates the pipeline and validates the Lp(a) thesis, while a failure would cement the competitive concerns. Amgen's diversified portfolio and ETF/index inclusion provide a floor, but the stock's 34% YTD run leaves it vulnerable to further de-rating if pipeline risk persists.
📝 Overview Generated automatically?
AMGN has been the subject of 16 signals across 16 articles in the last 365 days. Sentiment skews Bearish (81%).
Breakdown: 2 bullish, 13 bearish, 1 neutral. AI confidence averages 66% across all signals.
Most-cited catalysts: European regulators' recommendation to withdraw Tavneos (1×), Data integrity probe findings (1×), Upcoming results from the Phase III OCEAN(a)-Outcomes study for olpasiran (1×). Most-cited risk factors: Amgen successfully appeals the decision or submits new data to overturn the withdrawal (1×), The EU withdrawal has limited financial impact if Tavneos sales are minimal (1×), Negative read-through from Novartis's failed pelacarsen trial regarding the efficacy of Lp(a) reduction (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.